Polpharma Group | Partners

Our multi-regional pharmaceutical platform is open to partnerships.

From development and manufacturing to market access and commercialization, our platform gives partners the capabilities and reach to grow across markets.

BUILT ON RELATIONSHIPS

Strong partnerships are built on expertise, trust and shared responsibility.

We work closely with our partners across functions, markets and stages of development, combining scientific rigour with transparent communication and long-term commitment.

Successful partnerships require more than complementary capabilities. They depend on trust, clear responsibilities and teams that are prepared to work through complexity together.

sebastian szymanek

ceo of polpharma group

Why partner

Polpharma Group is a partner built for complex pharmaceutical collaboration.

Scientific expertise, operational strength and commercial experience give our partners a reliable foundation for developing products, scaling supply and building market presence.

Scientific depth

Specialised R&D capabilities support complex dosage forms, APIs and advanced technology platforms across a broad range of development needs.

6 R&D Centers

Operational strength

An established manufacturing network combines scale, specialised technologies and internal production capabilities across multiple pharmaceutical forms.

8 manufacturing sites

Commercial reach

Established B2B networks and local market expertise support partners across Europe and Central Asia and a broad international footprint.

100+ markets

Partnership models

Flexible partnership models for various partnership needs.

Hospital tender distribution

In-licensing

Out-licensing

Strategic R&D Partnership

Strategic partnerships

Technology transfer

API CDMO

A molecule with no route yet, developed from feasibility through to commercial supply, with the high-potent, oligonucleotide and cryogenic platforms available from the first step. Route assessment to CEP, EU and US DMF filing on one site, and contract manufacturing of an established substance runs as the commercial stage of the same model.

Your molecule. Our chemistry.

API Co-development

Joint ownership of a new substance neither side has carried alone: the Group brings chemistry, regulatory infrastructure and commercial-scale manufacturing, you bring target, clinical strategy and market access. Cost, IP and split agreed up front.

Shared cost. Shared upside.

API Supply

Direct supply of a substance already developed, registered and in routine production. The DMF is already filed in every market where you plan to launch, so there's no development cycle on your side. Batches release-tested to both Ph. Eur. and USP, so one lot covers either market. Capacity reserved on long-term supply terms.

Our portfolio. Your launch.

FDF CMO

Commercial-scale manufacturing of your finished form on qualified lines, packed, serialised and released to the standards of the markets you sell into, with QP release and lifecycle support.

Your dossier, our capacity & expertise.

FDF Co-development

A finished product designed around your active substance - formulation, process and dossier through bioequivalence - then carried to validated commercial supply on the Group's own FDF network, with shared risk available across the project.

Your molecule. Our dose form.

FDF Manufacturing

The Group's own portfolio made in plants every day under unified Quality System, on lines kept qualified and processes kept proven by continuous commercial production.

Our medicines, our plants.

Hospital tender distribution

When a partner holds the MA but wants reach without giving up ownership, the Group runs the commercial channel around their product - sales force, medical affairs, tender capability and logistics - mainly for the hospital channel across CEE.

Channel into our markets.

In-licensing

The Group commercialises registered partner products across CEE, CIS, Central Asia and Germany on its own infrastructure - MA holdership, regulatory affairs, reimbursement and tenders - with import and QP release for partners based outside the EU.

Your product. Our markets.

Out-licensing

A portfolio across prescription and consumer healthcare with dossiers to EU, FDA, EDQM, ANVISA and PMDA standards - hard-to-make generics, novel combinations and value-added formulations, plus a 100+ product pipeline - licensed to partners who register and sell in their own markets.

Your market. Our portfolio.

Strategic R&D Partnership

Longer-term alliances beyond a single transaction: joint research with universities and institutes alongside M&A, joint ventures, long-term supply and back-integration, co-owned where agreed and carried through to a registered product.

Multi-stage. Multi-year.

Strategic partnerships

Multi-stage. Multi-year.

Technology transfer

An existing product moved onto the network and made routine - method transfer, validation, scale-up and supplier qualification - to secure a second source or a larger, multi-market footprint.

Your product, our lines.

Our Portfolio

2000+ SKUs across prescription medicine and consumer healthcare, therapeutic areas, dossier jurisdiction, and licensing availability.

explore our Therapeutic groups

Our Markets

Fourteen direct markets, forty distribution markets, over one hundred B2B markets. Interactive map of where each commercial model applies.

explore our REACH

HOW WE PARTNER

The same standards, whatever the partnership model.

Every collaboration is different, but the principles behind it remain consistent: clear governance, rigorous quality, responsive teams and a shared commitment to long-term value.

Clear governance

Defined responsibilities, transparent communication and aligned expectations from the beginning of the partnership.

Quality by design

Scientific and quality standards embedded across development, manufacturing, supply and commercialization.

Responsive execution

Experienced teams and flexible cooperation models help projects move efficiently as requirements and market conditions evolve.

Aligned interests

Partnership structures designed around shared objectives, realistic responsibilities and sustainable value creation.

Long-term commitment

Relationships built to support continuity, adaptation and growth over the full lifecycle of the partnership.

Latest stories

featured

Science

July 1, 2026

Understanding the Oligonucleotide Market: A Foundation for Next‑Generation API Capabilities

Oligonucleotides drive fastest-growing API segment with 50% of pipelines using oligo-based candidates. Polpharma provides Nusinersen capabilities.

written by

Witold Kozak

Antonina Fryś

highlights

Science

June 3, 2026

Digital Twin at Polpharma API: Turning Manufacturing Data into Predictable Value

Digital Twin shifts manufacturing from reactive to preventive strategies. Compare batches against golden batch benchmarks to identify deviations in real time.

written by

Karol Sągol

Society

June 3, 2026

Broadening Access: How Generic APIs Are Shaping the Future of SMA Treatment

Spinal muscular atrophy affects 1 in 10,000 live births. Generic API suppliers expand global access to disease-modifying treatments for this genetic disorder.

written by

Antonina Fryś

Science

March 23, 2026

Antibody-Drug Conjugates (ADCs): Revolutionizing Cancer Treatment

ADCs deliver cytotoxic agents directly to cancer cells using monoclonal antibodies. The global market is projected to reach 27.8 billion USD by 2032.